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simple and useful tool for quantifying and exploring the (com-
bined) uncertainty associated with decision-making about adopt-
ing guidelines and implementation strategies and, therefore, for
informing decisions about efﬁcient resource allocation to change
clinical practice.
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OBJECTIVES: Estimation of cost-of-illness typically involves
the analysis of skewed medical costs that include large outliers.
Log transformations are frequently used to overcome these
problems. Linear regression models (OLS) are then applied to
the transformed data. The estimated model coefﬁcients are
retransformed back to the linear scale using the smearing
approach. Implementing this approach in statistical packages
requires customized programming. We propose an alternative to
using log transformations: Generalized Linear Models (GLM)
with a log link function. We compare the performance of both
models in estimating cost-of-illness. METHODS: We derived
data from a large administrative database representing 143,593
discharges from 39 US hospitals from January 2004 to Decem-
ber 2005. We estimated total medical costs among hospitalized
patients attributable to hyponatremia. Using a cross-validation
approach, we compared the performance of two models: log
transformed OLS with smearing and GLM with a log link func-
tion and a normal error distribution. We used the Root Mean
Squared Error (RMSE) and the Mean Absolute Error (MAE) to
assess model performance. Covariates in both models included
patient age, gender, race, geographic region, Deyo-Charlson
comorbidity index, primary diagnosis, teaching status of hospi-
tal, and admission source. All analyses were contacted using
SAS®. RESULTS: The GLM with log-link and a normal error
distribution had both the smallest RMSE (23,688) and MAE
(11,304) compared to the log transformed OLS with smearing
(24,057 and 11,392, respectively). Furthermore, by using GLM,
there was no need to compute a retransformation estimate, since
the log link function relates the response mean to the original
scale. CONCLUSIONS: In this cross-validation study, GLM
outperformed OLS with smearing. GLM is easier to implement
using SAS® with no need for retransformation estimates. Because
of its ease of use and statistical accuracy, GLM is a useful alter-
native to log-transformed OLS models with smearing, when
estimating cost-of-illness.
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OBJECTIVES: Reimbursement decisions are often supported by
economic evaluations based on randomised controlled trials
(RCTs). A problem with RCTs is that they usually deviate from
daily practice. Hence, reimbursement decisions are based on
perfect-world assessments of cost-effectiveness. In daily practice,
the technology is likely to be less cost-effective for instance due to
lower compliance. To make real-world reimbursement decisions,
factors that potentially inﬂuence the cost-effectiveness should be
considered. These factors are implementation factors, and sto-
chastic in nature. This study presents a framework that incorpo-
rates the implementation of a technology directly into the
economic evaluation, thus anticipating on potentially less than
perfect implementation. This results in real-world economic
evaluations. METHODS: The framework allows for a stepwise
consideration of the net beneﬁt (NB) of a technology in different
states of the world: 1) perfect-world (NB under perfect imple-
mentation); 2) real-world (NB under expected implementation);
and 3) improved-world (NB after intervention to improve imple-
mentation). Step 1 tells us whether the technology could be
cost-effective. Step 2 gives us the real world cost-effectiveness.
The difference between the NB of step 1 and 2 gives the upper
bound of the value of improving implementation. Step 3 tells us
whether it is cost-effective to invest in speciﬁc interventions to
improve implementation. The implementation factors are sto-
chastic, therefore in each step parameter uncertainty is addressed
in probabilistic sensitivity analyses, and the value of reducing
uncertainty is examined in value of information analyses.
RESULTS: As a case we used a Markov model that examines the
cost-effectiveness of direct hearing aid provision versus provision
by referral. Two stochastic implementation parameters were
incorporated: patient compliance and professional uptake. The
upper bound of the value of improving implementation was €50
million (patient compliance), €23 (professional uptake) and €72
million in total. This suggests that implementation interventions
may be valuable (results presented at the conference).
METHODS: CONCLUSIONS: This framework allows for real-
word economic evaluations to inform policy decisions.
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In 1996 the Washington Panel controversially recommended
valuing productivity costs (PC) in terms of QALYs. While this
recommendation was criticised, the Panel’s assumption, that
respondents in health state valuation (HSV) exercises take
income losses into account, could not be countered since there
was no evidence regarding what people consider in HSV exer-
cises. If they do consider income losses and if this changes HSV’s,
then all past economic evaluations that have included PC in the
numerator may have double counted these costs. Alternatively, if
respondents do not consider income losses then all past economic
evaluations that have not included PC in the numerator have
failed to account for sizeable societal costs. OBJECTIVES: To
recapture the debate surrounding the appropriate method for
including PC in health economic evaluations, to identify empiri-
cal evidence addressing the assumptions made by the Washington
Panel and to recommend a research agenda for the future.
METHODS: In this review we ﬁrst present and discuss the
human capital and friction cost approaches for capturing PC.
Then, the Washington Panel approach is highlighted and dis-
cussed. Next, we identify, outline and critically appraise the
existing empirical studies that attempt to address the assumption
that respondents to HSV exercises take income effects into
account. Finally, we outline a research agenda for the future that
will help to determine the most appropriate method for including
PC. RESULTS AND CONCLUSIONS: Only six empirical
studies were identiﬁed. The studies differ substantially in
methods and results and drawing general conclusions from them
is difﬁcult. Overall, it seems that not explicitly mentioning the
inclusion of income will induce a minority of respondents to
Abstracts A563
